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Abstract
Background: Proteolysis of huntingtin (Htt) plays a key role in the pathogenesis of Huntington’s disease (HD). However, the
environmental cues and signaling pathways that regulate Htt proteolysis are poorly understood. One stimulus may be the
DNA damage that accumulates in neurons over time, and the subsequent activation of signaling pathways such as those
regulated by IkB kinase (IKK), which can influence neurodegeneration in HD.
Methodology/Principal Findings: We asked whether DNA damage induces the proteolysis of Htt and if activation of IKK
plays a role. We report that treatment of neurons with the DNA damaging agent etoposide or c-irradiation promotes
cleavage of wild type (WT) and mutant Htt, generating N-terminal fragments of 80–90 kDa. This event requires IKKb and is
suppressed by IKKa. Elevated levels of IKKa, or inhibition of IKKb expression by a specific small hairpin RNA (shRNA) or its
activity by sodium salicylate, prevents Htt proteolysis and increases neuronal resistance to DNA damage. Moreover, IKKb
phosphorylates the anti-apoptotic protein Bcl-xL, a modification known to reduce Bcl-xL levels, and activates caspases that
can cleave Htt. When IKKb expression is blocked, etoposide treatment does not decrease Bcl-xL and activation of caspases is
diminished. Similar to silencing of IKKb, increasing the level of Bcl-xL in neurons prevents etoposide-induced caspase
activation and Htt proteolysis.
Conclusions/Significance: These results indicate that DNA damage triggers cleavage of Htt and identify IKKb as a
prominent regulator. Moreover, IKKb-dependent reduction of Bcl-xL is important in this process. Thus, inhibition of IKKb
may promote neuronal survival in HD as well as other DNA damage-induced neurodegenerative disorders.
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Introduction
Huntington’s disease is a neurodegenerative disorder caused by
expansion of a CAG repeat, which is translated into a
polyglutamine (polyQ) stretch in the N-terminus of Htt protein
[1]. Neurotoxicity in HD is attributed to the cleaved N-terminal
fragments of mutant Htt [2–4]. Wild type Htt is also cleaved and
inactivated by proteases, and its deletion in the central nervous
system (CNS) promotes neurodegeneration and is deleterious for
development [5–6]. The neuroprotective functions of WT Htt
include inhibition of caspase-3, induction and transport of brain-
derived neurotrophic factor (BDNF), and guarding against DNA
damage and excitotoxicity [7–11].
DNA double-stranded breaks progressively accumulate in the
aging brain, and elevated DNA damage is found in HD patients
and HD animal models [11–14]. The vulnerability of neurons to
DNA damage in HD is further exemplified by reduced expression
of nuclear proteins such as high mobility group B 1(HMGB1),
which protects against genotoxic stress [12,15]. Elevated expres-
sion of HMGBs protects against polyQ-induced neurotoxicity in
primary neurons and in a Drosophila polyQ model [15]. DNA
damage induced by oxidative stress is also an important factor in
the development of neurotoxicity and phenotypic changes in a
chemical model of HD [16]. Thus, accumulation of DNA damage
is a potential regulator of HD pathology. However, the
mechanism for how DNA damage influences neurotoxicity in
HD is not well understood. One contributing factor may be the
DNA damage-induced activation of p53 and IKK signaling
pathways, which have been implicated in HD neurotoxicity
[14,17–18].
DNA damage is a potent inducer of IKK [17]. The core
complex has two kinases, IKKa and IKKb, and a regulatory
subunit, IKKc [19]. As an activator of NF-kB, the IKK complex
regulates inflammation, cytokine production and cell survival. The
IKKb subunit is the predominant kinase responsible for
inflammatory responses [19]. Excessive IKKb activity is, however,
implicated in several neurodegenerative disorders, including HD,
Alzheimer’s disease (AD), and Parkinson’s disease (PD) [18,20–
21]. It is relevant that HD patients have chronically elevated levels
of inflammatory cytokines in the serum and CNS long before the
onset of symptoms [22], implying that persistent dysregulation of
IKK may occur early in the disease. In contrast, IKKa can repress
IKKb activity and reduces the production of inflammatory
cytokines [23]. IKKa also has neuroprotective properties and
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promotes memory reconsolidation in the hippocampus [24].
Moreover, nuclear IKKa inhibits the activity of tumor suppressor
p53 that is induced by DNA damage, and increases cellular
resistance to genotoxic stress [25]. P53 is elevated in HD brains
and reducing its activity ameliorates HD symptoms in animal
models [14].
We previously showed that HD mouse models have elevated
IKKb/NF-kB in the CNS, and blocking IKKb activity prevents
degeneration of medium-sized spiny neurons caused by a toxic
fragment of mutant Htt [18]. Here we report that DNA damage-
induced IKKb is an important activator of Htt proteolysis, while
IKKa inhibits this event. We present evidence for a signaling
network that involves phosphorylation and reduction of Bcl-xL by
IKKb, and subsequent activation of caspases, which can cleave Htt.
Results
DNA damage has opposite effects on IKKa and IKKb
In this study we used a human embryonic neuronal stem cell
line (MESC2.10) isolated from the midbrain of an eight-week-old
embryo [26], to characterize the signaling between DNA damage,
IKKb activation and Htt turnover. To establish the model,
MESC2.10 neuroblasts were differentiated and examined for
expression of neuronal markers. Upon differentiation, MESC2.10
cells acquire neuronal morphology (Fig. 1A) and express neuron-
specific proteins such as PSD-95, b-catenin and the neurofilament
Tuj-1 (Fig.1B, top two panels and 1C). These neurons can be
maintained for more than two weeks without significant apoptosis
(Fig. 1B, third panel). To induce DNA damage, we first used the
topoisomerase inhibitor etoposide, which produces DNA double-
stranded breaks in post-mitotic neurons [27]. The induction of
DNA damage in MESC2.10 neurons was confirmed by nuclear
staining of phosphorylated histone H2aX (c-H2aX), a surrogate
marker of DNA damage (Figs. 1C and 1D) [28]. We used an acute
etoposide treatment of 6 hr to avoid neuronal death, which occurs
after prolonged incubation [27].
To determine if DNA damage activates IKK in neurons we first
performed in vitro kinase assays using recombinant IkBa as the
substrate for IKKb complexes immunoprecipitated from the
extracts of etoposide-treated neurons. We find that IKKb is
activated 2 hrs after etoposide treatment and remains active for up
to 4 hrs (Fig. 2A top panel). These results are consistent with the
effects of etoposide on IKKb in non-neuronal cells [17]. We were
also interested in whether DNA damage influences IKKa activity,
since this subunit appears to play a prominent role in survival and
neuronal plasticity [24–25]. To obtain IKKa complexes devoid of
IKKb, neuronal extracts were first depleted by prior incubation
with anti-IKKc and -IKKb antibodies, and IKKa complexes were
subsequently immunoprecipitated. IKKa activity is routinely
tested in vitro by phosphorylation of IkBa, although in vivo this
Figure 1. Differentiation of MESC2.10 neurons and etoposide-induced DNA damage. (A) Neuroblasts were transduced with an EGFP
lentivirus. After differentiation for 9 days they were fixed and examined by a confocal microscope. TOTO-3 was used to stain the nuclei. (B) Synapse
markers in MESC2.10 neurons. Extracts from differentiated neurons (DPD, days post differentiation) were examined by Western blotting for
expression of b-catenin and PSD-95. Bottom panel shows Western blot analysis of lysates from neurons maintained for different time points in culture
stained for caspase-3 activation. (C) c-H2aX accumulates in the nuclei of etoposide treated MESC2.10 neuron. Differentiated neurons treated with
etoposide for 4hr were fixed and stained with a rabbit anti-c-H2aX (green). Anti-Tuj-1 was used to label the cytoplasm (red). Part (D) shows
accumulation of c-H2aX in the nuclear fraction of etoposide treated neurons over time examined by Western blotting with anti-c-H2aX antibody.
Lamin B1 was used as loading control.
doi:10.1371/journal.pone.0005768.g001
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phosphorylation is predominantly performed by IKKb [19].
Interestingly, MESC2.10 neurons display constitutive IKKa
activity (Fig. 2B, top lane 1). MESC2.10 neurons are grown in
complex medium with several growth factors, some of which
might be responsible for activation of IKKa. Longer treatment
with etoposide, however, reduces IKKa activity (Fig. 2B, lanes 4).
We also observe a decrease in the level of IKKa protein, which
may contribute to the low IKKa activity (Fig. 2B, bottom panel).
Thus, induction of DNA damage has opposite effects on the
activity of IKKa and IKKb in neurons.
DNA damage-induced proteolysis of Htt is regulated by
IKKs
Induction of p53 by DNA damaging agents promotes the
expression of Htt [29]. Consistent with these observations, we find
that treatment of MESC2.10 neurons with etoposide increases the
level of endogenous, full-length Htt ,4-fold (Fig. 3A, top panel,
asterisk, lanes 1–3). The elevation of Htt overlaps in time with
accumulation of nuclear p53 (Fig. 3B, top panel, lanes 1–4).
Longer exposure of neurons to etoposide induces proteolysis of
endogenous Htt, however, generating N-terminal fragments of
,80 kDa (Fig. 3A, top panel, lane 4, arrow). These data suggest
that accumulation of DNA damage in neurons activates
proteolytic enzymes that can cleave Htt.
To confirm that Htt cleavage is induced by DNA damage and not
other, secondary effects of etopoisde, we examined whether DNA
damage induced by c-irradiation of neurons could have a similar
effect on Htt cleavage. As expected, c-irradiation also generates an
Htt fragment similar in size to that produced by etoposide treatment
(Fig. S1). Interestingly, induction of Htt proteolysis by c-irradiation
occurs faster than etoposide treatment and is prominent by 4 hr
post-irradiation, whereas maximal Htt proteolysis induced by
etoposide requires ,6 hr. The difference maybe due to rapid
induction of double stranded DNA breaks by irradiation.
Since etoposide treatment reduces the level and activity of
IKKa (Fig. 2B), we examined whether increasing its level could
rescue the effects of DNA damage on Htt protein. MESC2.10
neurons were transduced with an IKKa lentivirus, which increases
the level of IKKa by ,3-fold (Fig. 3C). Indeed, this enables the
IKKa+ neurons to resist etoposide-induced Htt proteolysis (Fig. 3A,
top panel, lanes 5–8). IKKa+ neurons display a higher basal level
of full-length WT Htt than controls (Fig. 3A, compare lanes 1 and
5), and accumulation of p53 in IKKa+ neurons (Fig. 3B, top
panel, lanes 5–8) has no additional effect on Htt levels. The lack of
further Htt elevation in IKKa+ neurons may be due to inhibition
of p53 transcriptional activity by elevated IKKa [25]. While the
interaction between p53, IKKa and Htt expression remains to be
explored in detail, these findings support a protective role for
IKKa in reducing proteolysis of endogenous, WT Htt in neurons
with DNA damage.
In contrast, IKKb activity is induced by DNA damage (Fig. 2A).
Thus, we hypothesized that reducing its level may be protective.
Towards this end, we silenced IKKb expression with a specific,
anti-IKKb small hairpin RNA (shRNA) expressed from a
lentivirus (Fig. 4A), and treated the neurons with etoposide. We
find that, similar to the effect of elevating IKKa, silencing IKKb
expression reduces the proteolysis of Htt (Fig. 4B). Silencing of
IKKb expression or inhibition of its kinase activity by sodium
salicylate [30] also blocks Htt cleavage induced by c-irradiation
(Fig. S1, lanes 8 and 5, respectively). Thus, IKKb activation by
DNA damage promotes Htt cleavage, and increasing IKKa or
reducing IKKb blocks this event.
It is relevant that etoposide-induced IKKb activates p65 NF-kB
DNA binding in MESC2.10 neurons (Figs. 4C and D). Interest-
ingly, the DNA binding activity of p65 is significantly reduced in
neurons with elevated IKKa (Fig. 4C). While IKKa is known to
inhibit IKKb/NF-kB in immune cells [23], this has not been
reported for post-mitotic neurons. Therefore, the protective effects
of IKKa in response to DNA damage may include inhibition of
IKKb activity. However, inhibitors of NF-kB do not influence Htt
proteolysis, suggesting that IKKb regulation of Htt proteolysis is
NF-kB independent (see below). Etoposide has no effect on the
activation of p52 NF-kB in MESC2.10 neurons (Fig. 4D).
IKKs influence the DNA damage-induced activation of
pro-apoptotic caspases
Several caspases, including caspase-3 and -6, are known to
cleave Htt between amino acids 500–600 generating fragments
similar in size to those observed in our DNA damage paradigm
(Fig. 3A) [2–5]. To better understand the role of the IKKs in
Figure 2. Etoposide promotes IKKband inhibits IKKa. (A)
Etoposide activates IKKb. IKK complexes were immunoprecipitated with
anti-IKKc antibody coupled to protein G agarose beads and assayed for
kinase activity using GST-IkBa and 32P-c-ATP. Products were examined by
SDS-PAGE followed by autoradiography. The top panel shows kinase
activity (KA) and the lower panel shows a Western blot for IKKb of similar
immunoprecipitated complexes. (B) IKKa is constitutively active in
MESC2.10 neurons. Lysates were first treated with a combination of anti-
IKKb and IKKc antibodies coupled to agarose beads to deplete IKKc/IKKb/
IKKa complex. IKKa complexes were then immunoprecipitated with anti-
IKKa antibody conjugated to protein G agarose beads and assayed for
kinase activity as described in part A. The top panel shows IKKa activity
and the bottom panel shows the Western blot for IKKa. Fold changes of
IKK activity were quantified by measuring the band intensity using Image
J, and compared to non-treated neurons.
doi:10.1371/journal.pone.0005768.g002
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etoposide-induced Htt cleavage, we measured the activity of the
caspases. Both procaspase-3 and -6 levels are reduced after 6 hrs
of etoposide treatment (Fig. 5A, lane 4), which coincides with the
timing of Htt proteolysis (Fig. 3A, lane 4). Consistent with the
reduction of procaspases, the extracts of etoposide-treated neurons
display elevated caspase-3 and caspase-6 activities and are blocked
by specific caspase inhibitors (Figs. 5B and 5C, columns 2 and 3,
respectively). On the other hand, neurons with elevated IKKa
resist activation of procaspase-3 and procaspase-6 (Fig. 5A,
compare lanes 4 and 8). Moreover, extracts of etoposide-treated
IKKa+ neurons contain reduced caspase-3 and caspase-6 activity
(Figs. 5B and 5C, column 6, respectively). Blocking IKKb activity
with sodium salicylate, a potent inhibitor of IKKb [30], or
silencing its expression by shRNA also lowers the etoposide-
induced activation of caspases (Figs. 5B and 5C, columns 4 and 8,
respectively). Thus, the opposite effects of IKKa and IKKb on
caspase activation in the context of DNA damage may underlie
their differential effects on Htt cleavage.
DNA damage-induced IKKb regulates Bcl-xL
Activation of caspases can be triggered by several mechanisms,
including reduction in Bcl-xL [31]. The prosurvival protein Bcl-
xL, which is abundant in the CNS, has recently been implicated in
Htt proteolysis in a chemical model of HD [32–33]. We find that
the level of intact Bcl-xL is reduced in extracts of neurons treated
with etoposide (Fig. 6A, lane 6). In contrast, etoposide treatment
does not affect Bcl-xL in neurons with elevated IKKa or reduced
IKKb expression (Fig. 6A, lanes 2 and 4, respectively). To confirm
that Bcl-xL is important for blocking of DNA damage-induced Htt
proteolysis, we increased its expression in MESC2.10 neurons
using a recombinant lentivirus (Fig. 6B, second panel, lanes 3 and
4). As predicted, elevated Bcl-xL prevents Htt proteolysis by DNA
damage and this overlaps in time with prevention of caspase-3
activation (Fig. 6B first and third panels, respectively). Although
Bcl-xL expression prevents DNA damage-induced Htt cleavage,
some reduction in the level of full-length Htt is also observed.
Whether etoposide treatment induces production of other Htt
fragments that are not detected by this anti-Htt antibody and not
protected by Bcl-xL, remains to be investigated. Overall, these
studies indicate that Bcl-xL level is a critical component of caspase-
mediated Htt proteolysis induced by DNA damage, and is likely
influenced by IKKb.
The level of Bcl-xL mRNA in MESC2.10 neurons is not
affected by etoposide (data not shown), indicating that Bcl-xL
reduction is likely due to enhanced protein turnover. Although
phosphorylation-induced degradation of Bcl-xL in the presence of
genotoxic agents is a necessary step for induction of apoptosis, it is
unclear which kinase(s) mediates this event [31]. We tested the
possibility that activated IKKb phosphorylates Bcl-xL. To avoid
contamination with other neuronal kinases that may co-immuno-
precipitate with IKKb, we used recombinant IKKs for in vitro
kinase assays with Bcl-xL as the substrate. Indeed, IKKb
phosphorylates Bcl-xL (Fig. 6C, top panel), and this is specific
since inhibition of IKKb by sodium salicylate prevents this
reaction, and IKKa does not phosphorylate Bcl-xL. Thus, IKKb
is a novel kinase that modifies Bcl-xL and reduces its level in
stressed, post-mitotic neurons. This is consistent with the
unchanged levels of Bcl-xL in etoposide-treated neurons in which
IKKb expression has been silenced (Fig. 6A).
DNA damage-induced Htt proteolysis is polyQ-
independent
Generation of N-terminal fragments of mutant Htt is thought to
initiate neurotoxicity, culminating in HD [2–4]. We tested
Figure 3. Etoposide promotes Htt proteolysis and that is inhibited by elevated IKKa expression. (A) EGFP and IKKa-transduced neurons were
treated with 10 mM of etoposide for the indicated times. Extracts were examined for Htt by Western blotting. The top panel shows staining with anti-Htt
(mAb 2166) antibody. The asterisk indicates full-length endogenous Htt and the arrow shows the cleaved products. The second panel shows staining for
tubulin. Fold changes for full-length Htt levels were obtained by measuring the band intensity in each lane, normalized to tubulin and compared to non-
treated control. (B) p53 accumulates in the nucleus of etoposide treated neurons. Nuclear extracts fromMESC2.10 neurons were examined for the presence
p53 byWestern blotting. Lanes 1–4 are nuclear extracts fromMESC2.10 neurons with EGFP and lanes 5–8 are from neurons that were transduced with IKKa
lentiviruses (Fig. 1C). Staining with anti-lamin B1 was used to ensure equal loading (bottom panel). (C)Western blot analysis of IKKa levels in the control and
IKKa-expressing neurons. MESC2.10 neuroblasts were transduced with an IKKa recombinant lentivirus and differentiated as described in M&M. EGFP
lentivirus was used as a control. Top panel shows the Western blot for IKKa and bottom panel is staining of the same blot for tubulin.
doi:10.1371/journal.pone.0005768.g003
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whether DNA damage also promotes the proteolysis of full-length
mutant Htt. In a striatal neuronal line obtained from HD knock-in
mice (HdhQ111/Q111) [34], we find that etoposide treatment also
promotes cleavage of full-length, mutant Htt protein (Fig. 7, top
panel, lane 2). This proteolysis is blocked by inhibition of caspase-3
or IKKb activity (Fig. 7 top panel, lanes 3 and 4). Moreover,
cleavage of Htt overlaps in time with reduction of Bcl-xL, which is
prevented by inhibition of IKKb with sodium salicylate (Fig. 7,
second panel). Taken together, these results indicate that, in post-
mitotic neurons, DNA damage-activated IKKb facilitates Htt
proteolysis indirectly by promoting Bcl-xL turnover and activating
a caspase pathway. Thus, in the context of neuronal DNA
Figure 4. Inhibition of IKKb prevents proteolysis of Htt induced by etoposide. (A) MESC2.10 neurons were transduced with a control or
lentivirus expressing specific anti-IKKb shRNA. The level of IKKb protein was examined by Western blotting with an anti-IKKb antibody. Bottom panel
shows staining of same blot for a-tubulin. (B) Inhibition of etoposide-induced Htt cleavage by silencing of IKKb. Control or MESC2.10 neurons with
silenced IKKb were treated with etoposide for 6 hrs and examined for Htt cleavage (lanes 1 and 2) as described in Fig. 3A. Arrowhead indicates
position of full length Htt, and the arrow shows the position of the major cleaved product. The second panel shows IKKc levels used as a loading
control. (C) DNA binding activity of P65 NF-kB is increased by etoposide and is suppressed by IKKa. Binding to consensus NF-kB oligonucleotides and
detection was described in M&M. Lanes 1–4 show p65 binding from nuclear extracts of control and lanes 5–8 are from neurons transduced with a
lentivirus expressing IKKa (Fig. 3C). Bars indicate S.E.M. and asterisk shows significant difference between control and IKKa+ neurons treated with
etoposide for 4 hr, P,0.01 using a student’s t test. (D) Competition of etoposide-induced p65 NF-kB binding by consensus oligonucleotides. Nuclear
extracts of etoposide treated neurons were pre-incubated with 100 ng of competitor NF-kB oligonucleotides (Clontech) on ice for 1 hr (Column 3)
before treatment with etoposide for 6 hrs. Wells with mutated NF-kB DNA oligonucleotides were used to ensure specificity of the binding (column 4).
(E) Binding of p52 NF-kB to consensus oligonucleotides is not changed by DNA damage. Experiments were similar to in part C, except binding was
examined for p52. Bars indicate S.E.M. and asterisks show significant difference in binding between samples without or with the competitor
oligonucleotides or with p65 binding to mutated NF-kB oligonucleotides, P value ,0.01, using a student’s t test.
doi:10.1371/journal.pone.0005768.g004
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damage, IKKb activation is detrimental and its inhibition may be
protective in HD and potentially in other neurodegenerative
disorders where DNA damage plays a role.
Discussion
The novel aspects of present work are the triggering of Htt
proteolysis by DNA damage and the identification of IKKb as a
prominent regulator of enzymes known to cleave Htt. We propose
that in post-mitotic neurons, IKKb activation by DNA damage
promotes Htt cleavage by influencing Bcl-xL and a caspase
pathway. Conversely, our data support a protective role for IKKa,
whose expression in neurons prevents DNA damage-induced Htt
proteolysis (Fig. 8).
Although acute IKKb activation is known to be predominantly
pro-survival, under certain circumstances it promotes apoptosis
and neurodegeneration [20,35]. For example, conditional deletion
of IKKb delays apoptosis by inhibiting caspase-3 in regressing
mammary epithelial cells [35]. Aberrant activation of IKKb has
also been implicated in neurotoxicity in HD, PD, AD, multiple
sclerosis, and ischemia-induced neuronal death [18,21,36–38].
Our data indicate that activation of IKKb by DNA damage may
injure neurons by increasing the turnover of WT Htt. It is notable
that both WT and mutant Htt are cleaved in our DNA damage
paradigm. Neurons in HD brains, which have WT and mutant
copies of Htt, may therefore be susceptible to DNA-induced
damage on both counts. In addition to loss of WT Htt function,
cleavage of the mutant Htt could also generate toxic N-terminal
fragments that are amyloidogenic [4]. Thus, DNA damage-
induced IKKb in the HD brain may set in motion one of the
earliest events in HD pathology. Other insults such as chronic
exposure to pro-inflammatory cytokines, which are elevated in the
plasma and brain tissue of pre-symptomatic HD patients, may also
cause persistent activation of IKKb in neurons and further
exacerbate the cleavage of Htt [19,22]. A potential source for these
cytokines is the activated microglia that are detected in various
parts of HD brains, including striatum and hypothalamus [39,40].
It is interesting that deletion of IKKb in microglia reduces
neurodegeneration in a chemical model of HD by suppressing the
expression of pro-inflammatory cytokines [41]. While the role of
cytokines in IKKb-dependent Htt proteolysis remains to be
characterized, we can speculate that activation of IKKb in
neurons may trigger Htt proteolysis cell autonomously, as in the
induction of DNA damage, or non-autonomously by chronic
exposure to pro-inflammatory cytokines produced by microglia
(41). It is also of interest that inhibitors of IKKb reduce proteolysis
of amyloid precursor protein (APP) and subsequent Ab42
production [38]. The regulation of amyloidogenic proteins such
as Ab and N-terminal Htt fragments by activated IKKb is an
intriguing area for future work.
In contrast to IKKb, IKKa promotes neuronal survival and
prevents Htt proteolysis. This could simply result from suppression
of IKKb activity by IKKa (Fig. 4C) [23]. However, IKKa has
several other neuroprotective properties that could be important.
For example, IKKa activates CREB binding protein (CBP), a
transcriptional co-activator of many neuronal signaling pathways
including BDNF expression [25,42]. Enhancement of the histone
acetyltransferase activity of CBP is known to reduce the toxicity of
mutant Htt [43]. IKKa also inhibits the transcriptional activity of
p53, which has been implicated in HD pathogenesis, and
promotes neuronal plasticity and memory formation in the
hippocampus [14,24–25]. Thus, IKKa may prevent Htt proteol-
ysis independent of IKKb by modulating expression and/or
activation of gene products that antagonize the toxic effects of
Figure 5. IKKs influence etoposide-induced activation of
caspases. (A) Activation of caspase-3 and caspase-6. MESC2.10
neurons were treated with etoposide as in figure 3A and examined
for the levels of procaspase-3 (top panel) or procaspses-6 (middle
panel) by Western blotting. Arrow shows the cleaved products of
procaspase-3. (B and C) Caspase-3 (B) and caspase-6 (C) activities are
shown in MESC2.10 neuronal lysates. For the specific inhibitors neurons
were first pretreated with 20 mM of Ac-DEVD-CHO, caspase-3 inhibitor
(C3I) or 20 mM of Ac-VEID-CHO, caspase-6 inhibitor (C6I), or 5 mg/ml of
sodium salicylate (NaSal) one hr prior to etoposide treatment for 6 hrs.
Extracts were incubated with either caspase-3 substrate (DEVD
conjugated to p-nitroanaline) or caspase-6 substrate (VEID conjugated
to p-nitroanline) in a 96 well plate at 37uC for 1 hr. Enzyme activities for
caspase-3 (B) or caspase-6 (C) were measured in a microplate reader.
Results are shown as relative enzyme activity and represent averages of
three experiments. Bars indicate S.E.M. and asterisk shows significant
difference from etoposide treated control neurons (column 2), p,0.01,
using a student’s t test.
doi:10.1371/journal.pone.0005768.g005
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DNA damage. Further examination of IKKa using gene therapy
or compounds that selectively enhance its functions in vivo is
worthy of investigation in HD animal models.
The mechanism of Htt proteolysis is complex and probably
involves integration of multiple signaling pathways. Our results
identify Bcl-xL as a potential mediator of DNA damage-induced
Htt proteolysis (Fig. 6). Bcl-xL participates in neuronal survival,
Figure 6. Etoposide promotes reduction of Bcl-xL. (A) Extracts of
control and etoposide-treated MESC2.10 neurons were examined for
Bcl-xL by Western blotting. Neurons were treated with etoposide for
6 hrs. Top panel shows staining for Bcl-xL and the bottom panel
indicates IKKc as a loading control. Fold changes were normalized to
the intensity of loading control, and compared to that of untreated
control neurons (lane 5). (B) Bcl-xL expression prevents Htt proteolysis
by etoposide. MESC2.10 neuroblasts were transduced with a lentivirus
expressing Bcl-xL (Lanes 3 and 4) and treated with etoposide for 6 hrs.
EGFP-lentivirus was used a control (C). Top panel Western shows
blotting for Htt. Arrow indicates the full-length Htt and the arrowhead
shows the cleaved Htt products. Second and third panels show staining
for Bcl-xL and pro-caspase-3, respectively. IKKc levels were used as a
loading control. (C) IKKb phosphorylates Bcl-xL. Active recombinant
IKKa or IKKb were tested for the ability to phosphorylate Bcl-xL. The
kinase assay was performed as described in the M&M with recombinant
Bcl-xL as a substrate. Products were visualized by autoradiography. IkBa
was used as a positive control substrate for IKKa. The top panel shows
the kinase product (KA) and bottom panel shows the SDS-PAGE and
coomassie-blue staining of the substrates use in kinase assays.
doi:10.1371/journal.pone.0005768.g006
Figure 7. Etoposide induces proteolysis of endogenous mutant
Htt in neurons striatal (HdhQ111/Q111) neurons. The caspase-3
inhibitor (C3I, 20 mM) and sodium salicylate (NaSal, 5 mg/ml) were added
1 hr prior to the addition of 10 mM etoposide for 6 hrs. Processing of
samples was as described in figure 3A. Top panel shows Western blot
analysis of lysates for Htt. Arrow indicates the full-length Htt and the
arrowhead shows the cleaved products (,90 kDa). The second panel
shows the level of Bcl-xL. IKKc was used as loading control.
doi:10.1371/journal.pone.0005768.g007
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and its degradation results in synaptic degeneration [32]. Our
findings indicate that DNA damage reduces Bcl-xL levels in an
IKKb-dependent manner. A role for IKKb is supported by the
inability of etoposide to reduce Bcl-xL in neurons expressing an
shRNA targeting IKKb, or following pretreatment with sodium
salicylate, a potent inhibitor of IKKb (Figs. 6A and 7). We propose
that IKKb reduces Bcl-xL levels by phosphorylation (Fig. 6C), a
modification known to promote Bcl-xL degradation [31].
Phosphorylation-dependent reduction of Bcl-xL is suggested to
play a role in spinal cord neuronal injury and is implicated in Htt
proteolysis in the striatum of 3-nitropropionic acid injected mice
[33,44]. Thus, reduction of Bcl-xL may be the signal that leads to
activation of caspases that target Htt (Fig. 8). Inhibition of caspase-
3 activation and Htt proteolysis in neurons with elevated Bcl-xL
further supports this notion (Fig. 6B).
Environmental factors appear to play a role in the development
of HD, since the age of onset is variable among patients with
similar polyQ expansions [45]. Accumulation of DNA damage as
well as activation of modifiers that influence Htt proteolysis could
impact disease progression. Our data indicate that IKKb induced
by DNA damage in neurons can be very significant, and inhibition
of IKKb can prevent depletion of WT Htt as well as the
production of toxic N-terminal fragments of mutant Htt. It is
noteworthy that IKKb is itself activated by N-terminal fragments
of mutant Htt [18]. Thus, Htt proteolysis and IKKb activation can
form a toxic feedback loop that could promote neurodegeneration.
This cycle can be influenced by cytokines that are induced by
IKKb activation and which are elevated in HD patients [22].
IKKa, on the other hand, may act as a brake to suppress excessive
IKKb activation and reduce neurotoxicity (Fig. 8). Thus, the ratio
of IKKa to IKKb activity may be a determinant of Htt proteolysis
in stressed neurons. Identification of the IKKs as regulators of Htt
proteolysis offers novel targets to search for molecules that prevent
one of the earliest events in HD pathogenesis.
Materials and Methods
Antibodies and reagents
Anti-Htt (mAb 2166), and PSD-95 antibodies were purchased
from Millipore (Temecula, CA). Antibodies recognizing IKKc,
IKKb, caspase-3 and caspase 6 were purchased from Cell Signaling
Technology (Danvers, MA). Anti-IKKa was purchased from BD
Biosciences (San Diego, CA). Anti-Bcl-xL and anti-p53 antibodies
were from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-Tuj-
1 antibody was purchased from Covance (Berkeley, CA). Cell
fractionation and ECL detection kits including HRP-conjugated
secondary antibodies were from PIERCE Biotechnology (Rockford,
IL). Anti-c-H2AX antibody, caspase-3 and caspase-6 activity kits,
and recombinant Bcl-xL protein were obtained from R&D systems
(Minneapolis, MN). Anti-laminB1 antibody, DMEM/F12, N-2 and
B-27 media supplements were purchased from Invitrogen (Carls-
bad, CA). Fibroblast-growth factor-2 (FGF-2) was obtained from
Promega (Madison, WI). Sodium salicylate, etoposide, and caspase-
3 and caspase-6 inhibitors (Ac-DEVD-CHO and Ac-VEID-CHO,
respectively), and anti-tubulin antibody were purchased from
Sigma/Aldrich (St. Louis, MO). Recombinant active IKKa and
IKKb were purchased from Upstate Biotechnologies (Lake Placid,
NY). Consensus NF-kB oligonucleotides for p65 and p52 coated
onto 96 wells and the corresponding antibodies for binding
detection (TransFactor NF-kB p65 and p52) were purchased from
Clontech (Mountain View, CA)
Generation of MESC2.10 human neurons
The methods for generation and differentiation of MESC2.10
human neuroblasts have been reported previously [26]. Briefly,
neuroblasts obtained from an 8 week-old human embryo were
transduced with a retrovirus encoding a tetracycline-regulated v-
myc to promote proliferation. These neuroblasts were grown on
poly-lysine and laminin coated plates in DMEM/F12 in the
presence N2 and B-27 neuronal supplements (Invitrogen) and
20 ng/ml FGF-2 (Promega). To differentiate MESC2.10 cells,
proliferation medium was replaced DMEM/F12 medium con-
taining 2 mg/ml of doxycycline and 5 mM cAMP.
Mouse striatal neuronal precursors, HdhQ111/Q111, obtained
from homozygous knock-in mice were propagated as described
[34]. Differentiation was carried out in DMEM/F12 medium
containing N2 and B-27 supplements as described for MESC2.10
neurons.
Etoposide treatment, cell fractionation and Western
blotting
MESC2.10 cells, differentiated for 9 days, were treated with
10 mM etoposide for the periods indicated in each figure. Neurons
were harvested and separated into cytoplasmic and nuclear
fractions using the NE-PER kit (PIERCE) according to instruc-
tions. For most experiments we used ,120 mg of lysate for SDS-
PAGE and Western blotting with the indicated antibodies.
Reactive bands in Western blots were detected by enhanced
chemiluminescence (ECL) using a gel documentation system.
Sodium salicylate (5 mg/ml), caspase-3 inhibitor (Ac-DEVD-
CHO) and casapse-6 inhibitor (Ac-VEID-CHO) were added at
Figure 8. A schematic diagram showing a potential signaling
pathway for IKKb-mediated Htt proteolysis in MESC2.10
neurons. (A) DNA damage activates IKKb, which can phosphorylate
Bcl-xL and enhance its degradation (arrow 1). Reduction of Bcl-xL levels
triggers the activation of caspases, which cleaves Htt. IKKb inhibition
block degradation of Bcl-xL, caspases activation, and proteolysis of Htt.
Similar to the inhibition of IKKb, elevation of Bcl-xL also prevents
caspase activation and Htt proteolysis. On the other hand, etoposide
treatment reduces the activity of IKKa (arrow 2). This may enhance IKKb
activation and/or block expression of neuroprotective proteins that are
essential for interfering with caspase activation and maintaining Htt
levels. Elevated IKKa expressed from a lentivirus overcomes these
deficiencies and prevents Htt proteolysis.
doi:10.1371/journal.pone.0005768.g008
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20 mM 1 hr prior to etoposide treatment. To examine the effects
of etoposide on mutant Htt differentiated mouse striatal cells
(HdhQ111/Q111) were treated with etoposide and analyzed as
described for MESC2.10 cells.
Immunochemistry
Differentiated neurons on coverslips were treated with 10 mM
etoposide for 4 hr. Cells were fixed and stained with a rabbit
antibody that specifically recognizes H2aX phosphorylated at Ser
139 (c-H2aX) (1:500) (R&D systems). Anti-Tuj-1 was used to label
the cytoplasm (1:1000). Goat anti-rabbit conjugated to FITC
(green) and goat anti-mouse conjugated to rhodamine (red) was
used as secondary antibodies. Pictures were captured with a
confocal microscope.
Lentivirus production
IKKa was cloned into the lentiviral FUGW vector under the
control of a ubiquitin promoter [46]. An EGFP-lentivirus was used
as a control. The Bcl-xL cDNA was cloned from MESC2.10
neurons by RT-PCR using standard procedures and its identity
confirmed by sequencing. The cDNA was subsequently inserted
into FUGW lentiviral vector. The shRNAs for IKKb cloned in a
lentiviral backbone was purchased from Open Biosystems
(Huntsville, AL). Lentiviruses were produced by transfection of
293 cells using calcium phosphate precipitation [46]. Supernatants
of virus-producing cells were harvested 48 hr post-transfection and
concentrated on Amicon Ultra columns (Millipore, MA). An
EGFP virus was used as a control to monitor viral titer. A
multiplicity of infection of 4:1 was used to infect MESC2.10
neuroblasts. Expression of IKKa, Bcl-xL and reduction of IKKb
were determined by Western blotting.
Kinase assay
IKKb activity was assayed as described previously [18]. To
determine IKKa activity, lyastes were first depleted of IKKb
complexes using 4 mg of anti-IKKc and anti-IKKb antibodies
coupled to protein G. The depleted lysates were used to isolate
IKKa complexes with 2 mg of anti-IKKa antibody. GST-IkBa
was used as a substrate to measure kinase activity. To examine
whether IKKs phosphorylate Bcl-xL, 0.5 mg of either IKKa or
IKKb were incubated with 1 mg of full-length Bcl-xL in the
presence of 32P-c-ATP for 30 min at 30uC. GST protein was used
as a negative control. All kinase products were examined by SDS-
PAGE and autoradiography.
Assay of NF-kB binding to consensus DNA
oligonucleotides
Nuclear extracts for control or etoposide-treated MESC2.10
neurons were obtained using the cell fractionation kit from pierce
according to the instructions provided. Fifty mg of each nuclear
extract was incubated for an hour at RT on 96 well plates (Clonetech,
Mountain View, CA) coated with consensus NF-kB oligonucleotides
(p65 or p52). Mutated NF-kB oligonucleotides were used to confirm
binding specificity. For competition assays, nuclear extracts were pre-
incubated with NF-kB oligonucleotides for 1 hr on ice and then
added to the coated wells. After washing, each well was incubated
with anti-p65 or anti-p52 antibodies for 30 min at 37uC. Wells were
washed as recommended by the manufacturer (Clontech), followed
by incubation with a secondary antibody conjugated to HRP. TMB
(3, 39, 5, 59-tetramethylbenzidine) was added for 10 min. Binding was
measured in a microplate reader at 655 nm.
Caspase assay
To measure the activity of caspase-3 or -6, the colorimetric assay
kits from R&D Systems were used according to manufacturer’s
instructions. Briefly, MESC2.10 neurons were pre-incubated with
caspase-3 inhibitor (Ac-DEVD-CHO), casapse-6 inhibitor (Ac-
VEID-CHO) or sodium salicylate (5 mg/ml) 1 hr prior to etoposide
treatment, which was for an additional 6 hrs. Cells were lysed as
instructed. Fifty mg of each lysate was incubated with either caspase-
3 substrate (DEVD conjugated to p-nitroanaline) or caspase-6
substrate (VEID conjugated to p-nitronalaine) in a 96 well plate at
37uC for 1 hr. Enzyme activities for caspase-3 or -6 were measured
with a microplate reader at 405 nm. Results are shown as relative
enzyme activity and represent average of three experiments.
Supporting Information
Figure S1 c-irradiation induced DNA damage promotes Htt
cleavage in MESC2.10 neurons. c-irradiation was carried out
using a MARK-I c-irradiator with a 137Cs source at a specific
dose rate of 1.22 Gy/min. Cells were irradiated with 5 Gy and
further incubated for the indicated time. Sodium salicylate (NaSal,
lane 5) was added at a concentration of 5 mg/ml 1 hr prior to
irradiation and incubated for 6 hr. Etoposide treatment (10 mM)
was used as a positive control and was carried out for 6 hr (lane 6).
Lanes 7 and 8 represent MESC2.10 neurons transduced with an
IKKb shRNA lentivirus (Fig. 4A) and irradiated with 5 Gy for
6 hr. The asterisk shows full-length Htt and the arrow indicates
the cleaved products. Tubulin was used as a loading control.
Found at: doi:10.1371/journal.pone.0005768.s001 (4.20 MB TIF)
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